Home › Research › Long-term cohort studies
Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease
Halawa OA, Gatchel JR, Amariglio RE, Rentz DM, Sperling RA, Johnson KA, Marshall GA, Alzheimer’s Disease Neuroimaging Initiative.. Alzheimer's research & therapy, 2019-01-31
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background A decline in instrumental activities of daily living (IADL) correlates with the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia and has been associated with frontal and parietal hypometabolism, lower cerebrospinal fluid amyloid β 1-42 , and inferior temporal cortical thinning. Identifying the underlying biomarkers of functional decline will allow for the early identification of individuals at risk of disease progression. Objective To investigate the association between IADL impairment and in vivo regional cerebral tau and cortical amyloid deposition across clinically normal (CN) elderly, MCI, and AD dementia.
What this study adds
Evidence grade: Low
This is a cross-sectional study. This study explored whether tau and amyloid in specific brain regions are linked to difficulty with daily activities in people with normal thinking, mild cognitive impairment, or Alzheimer's dementia. Identifying such biomarkers could help spot people at risk of decline earlier, though this was a small cross-sectional study.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Halawa, O. A., Gatchel, JR., Amariglio, R. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., et al. (2019). Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-019-0471-6
Vancouver
Halawa OA, Gatchel JR, Amariglio RE, Rentz DM, Sperling RA, Johnson KA, et al. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimer's research & therapy. 2019. doi:10.1186/s13195-019-0471-6. PMID: 30704519.
BibTeX
@article{halawa2019-30704519,
author = {Halawa, O. A. and Gatchel, JR. and Amariglio, R. E. and Rentz, D. M. and Sperling, R. A. and Johnson, K. A. and Marshall, G. A. and {Alzheimer’s Disease Neuroimaging Initiative}},
title = {{Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2019},
doi = {10.1186/s13195-019-0471-6},
pmid = {30704519},
url = {https://doi.org/10.1186/s13195-019-0471-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Identifying the underlying biomarkers of functional decline will allow for the early identification of individuals at risk of disease progression.
- Objective To investigate the association between IADL impairment and in vivo regional cerebral tau and cortical amyloid deposition across clinically normal (CN) elderly, MCI, and AD dementia.
- Methods Fifty-one CN elderly, 30 MCI, and 9 AD dementia participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent assessment of regional tau deposition with flortaucipir (FTP) positron emission tomography (PET).
- An aggregate of cortical amyloid burden was assessed by florbetapir PET.
Why it matters
This study explored whether tau and amyloid in specific brain regions are linked to difficulty with daily activities in people with normal thinking, mild cognitive impairment, or Alzheimer's dementia. Identifying such biomarkers could help spot people at risk of decline earlier, though this was a small cross-sectional study.
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 49 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.4 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 3.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Gad A. Marshall: h-index 75 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30704519) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-019-0471-6
- PubMed: 30704519
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Long-term cohort studies from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.